ACBI3 molecule offers recent hope for fighting KRAS mutations in cancer

KRAS is probably the most commonly mutated gene in cancer. Mutations occur in 17-25% of all cancers and affect thousands and thousands of patients worldwide. It plays an important role in tumor growth as it is necessary for the uncontrolled spread of tumor cells. Targeting KRAS function is a significant focus of cancer drug research. Nonetheless, currently approved treatments can only treat one in all many KRAS gene mutations, G12C, leaving greater than half of patients with KRAS-related cancers and not using a targeted treatment option.

Developed by multidisciplinary teams within the laboratory of Professor Alessio Ciulli and Boehringer Ingelheim, the ACBI3 molecule is predicated on a category of small molecules called PROteolysis TArgeting Chimeras (PROTACs). ACBI3 has been shown to rapidly eliminate 13 of the 17 most typical KRAS mutants with high potency and selectivity. KRAS knockdown by ACBI3 was also stronger than using small molecule KRAS inhibition and induced effective tumor regression in mouse models, confirming KRAS knockdown as a novel therapeutic concept.

It’s exciting to be working with Boehringer Ingelheim to explore a brand new therapeutic approach for therefore many cancer patients in need.”

Professor Ciulli, Director of CeTPD, corresponding creator of the study

“By joining forces with external partners who share our vision and drive to develop recent medicines, and with leading scientists corresponding to Prof. Ciulli, one in all the world pioneers in the sector of PROTACs and molecular adhesives, we will unlock the complete potential of novel therapeutic approaches,” said Dr. Peter Ettmayer, co-author of the study and Head of Drug Discovery Vienna at Boehringer Ingelheim.

Fighting tumor cells in recent ways

PROTACs represent a brand new class of potential drugs which have the potential to focus on cancer targets that were previously considered untreatable by drugs.

PROTACs are made up of two-pronged small molecules. One “prong” binds to the disease-causing goal protein. The opposite “prong” recruits a protein called E3 ligase, which is a component of the cell’s natural waste disposal system (the ubiquitin proteasome). Once they’re in close proximity, the E3 ligase marks the goal protein and labels it as “expired,” so it’s then rapidly degraded by the ubiquitin proteasome.

Discover ACBI3

To reach at this substance, the team, jointly led by Johannes Popow, Christiane Kofink and Andreas Gollner at Boehringer Ingelheim in Vienna and William Farnaby in Dundee (co-first authors), got down to directly attack as broad a spectrum of oncogenic KRAS mutations as possible by specifically developing degraders for these mutations, fairly than attempting to inhibit them, which is probably the most commonly used approach for cancer targets.

Starting with high-quality small molecules that form “tines” for KRAS at one end and are linked to the protein E3 ligase von Hippel-Lindau (VHL) at the opposite end, they identified a primary compound that showed great promise for bringing the 2 proteins closer together in a way that “sticks” them together, a property also known as “molecular glue.” This provided the team with a sexy start line for further investigation.

The team managed to crystallize the three components KRAS, PROTAC and VHL together. Using X-ray crystallography, they were in a position to visualize the structure of this complex in atomic detail and thus understand how the small molecule was in a position to recruit the 2 proteins together. Based on this understanding, the team was in a position to improve the compound and increase its activity as a degrader step-by-step, in a rational and targeted manner.

Joining forces with the worldwide scientific community

Importantly, Boehringer Ingelheim plans to make the KRAS degrader ACBI3 available to the scientific community freed from charge and with none strings attached through its opnMe® portal, which could advance future research toward this vital goal.

opnMe® is Boehringer Ingelheim’s Open Science portal. It leverages innovation by connecting one of the best experts from around the globe with Boehringer scientists. opnMe^® promotes independent scientific innovation with free, high-quality molecules for research purposes, research grants for brand new ideas on chosen molecules or scientific questions, and postdoc fellowships.

“By making this tool available to all the research community, scientists can study the implications and potential of degrading a very important carcinogenic protein, with the final word goal of fixing the lives of cancer patients,” added Dr. Ettmayer.